Peroxisome proliferator-activated receptor gamma

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 28, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, IND, RXRA, Biotechnology, Drug discovery, Cancer, Retinoid X receptor alpha, Flare, Disease, Recurrence, Squamous cell carcinoma, Peroxisome proliferator-activated receptor gamma, Inflammation, Senior, HIV disease progression rates, Neurology, Neoplasm, Patient, Bladder cancer, FGFR3, RWD, Lists of diseases, Third Rock Ventures, Therapy, UC, Investigational New Drug, Knowledge, Incidence, Factor X, Pharmaceutical industry, PPARG, Biology

Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.

Key Points: 
  • Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.
  • This disease has high rates of recurrence and the five-year survival rate is approximately 5% in metastatic cases.
  • The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC patients.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

X-linked Adrenoleukodystrophy Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, News, Peroxisome proliferator-activated receptor gamma, FTD, Degenerative disease, BBB, Pioglitazone, Clinical trial, Spinal cord, ABCD1, Neuroprotection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NAC, Toxicity, Food, Human, Oxidative stress, CNS, Fast track (FDA), ALD, Brain, Endocytosis, Microglia, AMN, PPAR, ABCD2, Patient, Cell, II, Inflammation, MPC, Plasma, RATS, VLCFA, Discovery, Animal, Vance DeGeneres, Adenosine, FDA, Disease, Astrocyte, Macrophage, Neurodegeneration, Therapy, AMPK, Pharmaceutical industry, Medical imaging, Medical device, Adrenoleukodystrophy

The "X linked Adrenoleukodystrophy - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "X linked Adrenoleukodystrophy - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The "X linked Adrenoleukodystrophy - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X linked Adrenoleukodystrophy pipeline landscape.
  • Companies and academics are working to assess challenges and seek opportunities that could influence X linked Adrenoleukodystrophy R&D.
  • This segment of the X linked Adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

MEDIA RELEASE (PDF) Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19

Retrieved on: 
Tuesday, April 12, 2022
Pioglitazone, Ventilation, Hospital, Peroxisome proliferator-activated receptor gamma, World Health Organization, WHO, Trial of the century, MAPK, Swiss Federal Nuclear Safety Inspectorate, Mortality, Data monitoring committee, Vaccine, Idiopathic pulmonary fibrosis, World, EudraCT, Public health, COVID-19, PPAR, Disease, Program, DSMB, Extracorporeal membrane oxygenation, ECMO, ICU, Idiopathic disease, Acquisition, Patient, SIX Swiss Exchange, Pharmaceutical industry, Muthiri kinaru, Omicron

Phase 2 trial assesses Kinarus' oral therapy, KIN001, to reduce mortality and the need for respiratory support in hospitalized COVID-19 patients

Key Points: 
  • Phase 2 trial assesses Kinarus' oral therapy, KIN001, to reduce mortality and the need for respiratory support in hospitalized COVID-19 patients
    Basel, Switzerland, April 12, 2022.
  • Kinarus AG ('Kinarus'), a Swiss clinical-stage biopharmaceutical company announced today that the independent Data and Safety Monitoring Board ('DSMB') has completed its interim safety review of the Kinarus Phase 2 KINETIC study.
  • DSMB recommends that the study continue as designed with Kinarus' oral therapy, KIN001, for treating hospitalized patients with severe COVID-19.
  • The unblinded interim safety review by the DSMB was conducted after the enrollment and completion of the first 40 patients.

Gastrointestinal Stromal Tumor (GIST) Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Health, General Health, BCR-ABL, GIST, VEGF, Novartis, PPAR, Ripretinib, Incidence, Peroxisome proliferator-activated receptor gamma, Clinical trial, Probability, Gastrointestinal stromal tumor, FMS, CD135, Pharmaceutical industry

The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.
  • The publisher estimates that in 2019, there were 100,200 incident cases of gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to 109,000 incident cases by 2028.
  • Novartis leads industry sponsors with by far the highest overall number of clinical trials for GIST.

Huntington's Disease Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Health, Biotechnology, Ageing, Patient, Central nervous system, Peroxisome proliferator-activated receptor gamma, Disease, CNS, Probability, NMDA, Pfizer, SIRT1, PPAR, Bausch Health, HD, MAP, Huntington's disease, Learning disability, Huntingtin, JHD, CAG, Psychiatry, Valbenazine, Dementia, Pharmaceutical industry, Teva

The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.
  • Huntington's disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells.
  • It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia.
  • The length of the CAG repeats is inversely associated with the age of disease onset - the longer the repeat, the earlier the onset.

EQS-News: Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines

Retrieved on: 
Monday, December 20, 2021
Pioglitazone, Executive Schedule, Federal Council, Federal, Severe acute respiratory syndrome coronavirus 2, PPAR, Public, Peroxisome proliferator-activated receptor gamma, Patient, Cytokine, MAPK, Program, Omicron, Fibrosis, CHF, 2015 Swiss Federal Council election, Pharmaceutical industry, Research, COVID-19, Swiss, Muthiri kinaru, KIN001, the Swiss Federal Funding Programme for COVID-19 Medicines, Kinarus, KIN001, THE SWISS FEDERAL FUNDING PROGRAMME FOR COVID-19 MEDICINES, KINARUS

Kinarus AG, a Swiss clinical-stage biopharmaceutical company announced today that it has been awarded a grant in the amount of 7 million CHF from the Swiss Federal Funding Programme for COVID-19 Medicines.

Key Points: 
  • Kinarus AG, a Swiss clinical-stage biopharmaceutical company announced today that it has been awarded a grant in the amount of 7 million CHF from the Swiss Federal Funding Programme for COVID-19 Medicines.
  • The funds from the COVID-19 medicines program will enable Kinarus to rapidly advance both clinical trials.
  • The Federal Funding Programme for COVID-19 Medicines aims to support innovative pharmaceutical projects that make a contribution to the rapid supply of COVID-19 medicines for the Swiss population.
  • Kinarus is actively enrolling patients in the KINETIC Phase 2 clinical trial of KIN001 in hospitalized COVID-19 patients.

CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
Hypoglycemia, Liver, NASDAQ, U.S. Securities and Exchange Commission, European Medicines Agency, Conference call, Clinical trial, CEO, COVID, Research, PBC, Primary biliary cholangitis, Itch, Disease, Investor, GPR119, Hepatitis, Therapy, Twitter, GLOBE, NASH, PSC, Pharmacokinetics, Food and Drug Administration, Peroxisome proliferator-activated receptor gamma, Annual report, Conference, Health, Security (finance), Patient, LinkedIn, Ursodeoxycholic acid, Â, Investment, Fibrosis, Leona, Priority, Thrombocytopenia, Alkaline phosphatase, T1D, Safety, Pharmaceutical industry, Medicine, Animal

NEWARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2021.

Key Points: 
  • ET
    NEWARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2021.
  • Second Quarter and Six Months Ended June 30, 2021 Financial Results
    Research and development expenses for the three months ended June 30, 2021 and 2020 were $16.7 million and $7.9 million, respectively.
  • Research and development expenses for the six months ended June 30, 2021 and 2020 were $29.1 million and $17.5 million, respectively.
  • General and administrative expenses for the three months ended June 30, 2021 and 2020 were $6.5 million and $3.2 million, respectively.

INDIGO Expands Discovery Platform to Include Zebrafish Assays

Retrieved on: 
Thursday, January 23, 2020
Branches of biology, Transcription factors, Intracellular receptors, Proteins, Cell biology, Peroxisome proliferator-activated receptor gamma, Nuclear receptor, Androgen receptor, Estrogen receptor, Peroxisome proliferator-activated receptor

STATE COLLEGE, Pa., Jan. 23, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio.

Key Points: 
  • STATE COLLEGE, Pa., Jan. 23, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio.
  • "The addition of zebrafish assays to INDIGO's portfolio gives discovery scientists the ability to make key determinations on the correct animal model for their research with an ortholog that was not previously available before entering animal trials.
  • The four new zebrafish nuclear receptor assays available from INDIGO include the Androgen Receptor (AR), Estrogen Receptor Alpha (ERA), Peroxisome Proliferator-Activated Receptor Gamma (PPARG), and Thyroid Receptor Beta (TRB).
  • INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making.

Cirius Therapeutics to Present Preclinical Data for Lead Drug Candidate in NASH at The International Liver Congress

Retrieved on: 
Wednesday, March 27, 2019
Medical specialties, Hepatitis, Medicine, Branches of biology, Transcription factors, Non-alcoholic fatty liver disease, Intracellular receptors, Steatohepatitis, Peroxisome proliferator-activated receptor gamma, Nash, MSDC

The presentations are as follows:

Key Points: 
  • The presentations are as follows:
    Title: Effect on MSDC-0602K treatment on the metabolome of a diet-induced murine model.
  • (Abstract FRI-289)
    Title: MSDC-0602K, a PPAR-gamma sparing modulator of the mitochondrial pyruvate carrier, improves NASH outcome in a diet-induced animal model of non-alcoholic steatohepatitis.
  • Our lead product candidate, MSDC-0602K, is a novel small molecule being developed as a once-daily oral therapy to treat NASH with fibrosis.
  • We are conducting a Phase2b clinical trial of MSDC-0602K, which we have fully enrolled with 402 patients diagnosed with NASH with fibrosis.